Madrid, 5^th July 2023. APICES, a Spanish CRO with 15 years of experience in clinical research, has announced the integration of Kappa Santé, a French CRO with extensive experience in clinical research, which offers its clients innovative studies based on the use of information technologies and artificial intelligence.

With this integration, the APICES Group continues its expansion towards its goal of becoming a leading European CRO. Furthermore, the APICES group would exceed 100 employees and a cumulative experience of more than 450 clinical research projects.

For Óscar Salamanca, CEO of APICES, “the incorporation of Kappa Santé into the Group is a major step in our plans for international growth as a company. In addition, the combined knowledge and experience of both companies strengthens our position in the market and boosts our growth, which will help us to solve more effectively the challenges of our clients in the study design, clinical development planning and the achievement of objectives to maximise the success of the projects“.

“In an increasingly complex environment in which more and more elaborate studies are designed, having staff with more than 20 years of experience in clinical research in your team provides you with the confidence to achieve the planned objectives in each of the projects and to provide added value to our clients”.

According to Ana Moreno, Global Clinical Operations Director of APICES, “Kappa Santé will allow us to reinforce our know-how and know-who and to continue carrying out clinical research projects efficiently, with the highest quality and always focused on meeting deadlines and customer satisfaction. The close and continuous monitoring of the project allows us to meet the deadlines agreed with the client for the development of the project and the flexibility allows us to adapt to their needs at any time. Our experience and the availability of all the resources within APICES allows us to maintain our philosophy of customer orientation, flexibility and quality”.

“APICES team has expertise in many therapeutic areas, being a widely recognised company in oncology and hematology; we conduct phase I-IV clinical trials, real world evidence (RWE) studies and artificial intelligence-based studies; we conduct studies with drugs and advanced therapies, medical devices, nutraceuticals and biomarkers among others, providing full clinical research services”.